Pembrolizumab for ultra-rare sarcoma types
Treatments studied
Part of Cancer clinical trials.
This trial tests whether pembrolizumab, an immunotherapy that helps your immune system attack cancer cells, can shrink or slow growth in several ultra-rare sarcoma types that have come back or spread. It may be an option if your previous treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have one of these specific rare sarcoma types: pleomorphic liposarcoma, PEComa, epithelioid sarcoma, CIC-rearranged sarcoma, or sclerosing epithelioid fibrosarcoma/low grade fibromyxoid sarcoma
- Your cancer has returned or spread and cannot be cured with standard treatments
- You have had 1 to 3 prior treatments (including chemo, targeted therapy, or hormonal therapy) and your cancer got worse or you stopped due to side effects
- Be at least 18 years old and have good organ function (kidneys, liver, blood counts) as determined by blood tests
- Have not taken an anti-PD-1/PD-L1 drug before, and do not have an active autoimmune disease that required treatment in the last 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pembrolizumab along with chemotherapy delivered directly into an arm or leg (isolated limb infusion) can shrink sarcoma tumors. It is for people with advanced or metastatic sarcoma in an arm or leg who can safely have this local treatment.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.